Ticagrelor

Generic Name: Ticagrelor

Brand Names: Brilinta, Brilique

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈F_₂N_₆O_₄S

CAS Number: 274693-27-5

Unique Ingredient Identifier: GLH0314RVC

Background: Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication: Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions: Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)

Associated Therapies: -

Clinical Trials

Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.

Phase 3

Completed

Conditions: Platelet Reactivity

Interventions: Drug: Ticagrelor
Drug: Clopidogrel and Ticagrelor

First Posted Date: 2013-10-11

Last Posted Date: 2015-08-20

Lead Sponsor: University of Patras

Target Recruit Count: 74

Registration Number: NCT01961856

Locations: 🇬🇷
Patras University Hospital, Patras, Achaia, Greece

Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease

Phase 4

Completed

Conditions: Endothelial Function
Coronary Artery Disease

Interventions: Drug: Ticagrelor
Drug: Prasugrel

First Posted Date: 2013-10-08

Last Posted Date: 2017-01-10

Lead Sponsor: University of Patras

Target Recruit Count: 22

Registration Number: NCT01957540

Locations: 🇬🇷
Patras University Hospital, Patras, Achaia, Greece

OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel
Drug: Cilostazol
Drug: Ticagrelor

First Posted Date: 2013-10-07

Last Posted Date: 2020-08-18

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 1724

Registration Number: NCT01955200

Locations: 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Phase 4

Completed

Conditions: Acute Coronary Syndrome (ACS)

Interventions: Drug: Ticagrelor
Drug: Prasugrel

First Posted Date: 2013-09-18

Last Posted Date: 2023-02-06

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 4018

Registration Number: NCT01944800

Locations: 🇩🇪
Universitäts-Herzzentrum Freiburg/ Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany
🇩🇪
Universitäts-Klinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇩🇪
Universitätsklinikum Mannheim, Mannheim, Baden-Württemberg, Germany

and more 16 locations

Ticagrelor for PCI Post Thrombolysis

Phase 3

Completed

Conditions: Acute Myocardial Infarction

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-08-29

Last Posted Date: 2016-11-22

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 140

Registration Number: NCT01930591

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦
Southlake Regional Health Centre, Newmarket, Ontario, Canada
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

and more 2 locations

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor
Drug: Eptifibatide

First Posted Date: 2013-08-09

Last Posted Date: 2017-02-28

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 70

Registration Number: NCT01919723

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Phase 4

Completed

Conditions: Plaque, Atherosclerotic

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-07-23

Last Posted Date: 2016-02-26

Lead Sponsor: CHEOL WHAN LEE, M.D., Ph.D

Target Recruit Count: 50

Registration Number: NCT01905566

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2013-07-10

Last Posted Date: 2017-04-24

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 36

Registration Number: NCT01894789

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

Phase 1

Completed

Conditions: Community Acquired Pneumonia
Hospital Acquired Pneumonia
Pneumonia
Acute Lung Injury

Interventions: Drug: placebo
Drug: ticagrelor

First Posted Date: 2013-06-21

Last Posted Date: 2018-09-13

Lead Sponsor: University of Kentucky

Target Recruit Count: 60

Registration Number: NCT01883869

Locations: 🇺🇸
University of Kentucky Hospitals, Lexington, Kentucky, United States
🇺🇸
University of Kentucky Hospital, Lexington, Kentucky, United States

Brilinta DaYu Study

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor

First Posted Date: 2013-06-06

Last Posted Date: 2018-04-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 2004

Registration Number: NCT01870921

Locations: 🇨🇳
Research Site, Zhongshan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy